Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr;20(2):e136-49.
doi: 10.3747/co.20.1252.

Lenalidomide in multiple myeloma-a practice guideline

Affiliations

Lenalidomide in multiple myeloma-a practice guideline

C Chen et al. Curr Oncol. 2013 Apr.

Abstract

Background: Promising new drugs such as lenalidomide, an immunomodulatory agent, are available for the treatment of multiple myeloma. We describe the process of creating a provincial guideline for the use of lenalidomide, alone or in combination with other drugs, in relapsed, refractory, or newly diagnosed disease (including smoldering and symptomatic patients, and candidates and non-candidates for transplant) and in maintenance treatment (after transplant or non-transplant therapy); and for strategies to manage lenalidomide-related toxicities.

Methods: Outcomes of interest included overall survival, event-free survival, progression-free survival, time to progression, time to next treatment, response rate, and incidence of serious toxicity. The medline, embase, and Cochrane Library databases, as well as meeting abstracts and the Web sites of relevant organizations, were systematically searched for relevant literature.

Results: Recommendations were developed using the evidence from published studies and the clinical expertise of the working group and of the Cancer Care Ontario Hematology Disease Site Group.

Conclusions: Lenalidomide in combination with dexamethasone can be recommended for both previously untreated and treated patients with multiple myeloma. Guidelines for the management of cytopenias, venous thromboembolism, and second primary malignancies are discussed.

Keywords: Lenalidomide; imid; multiple myeloma; practice guideline.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Study flow chart.

References

    1. Weber DM, Chen C, Niesvizky R, et al. on behalf of the Multiple Myeloma (009) Study Investigators Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133–42. doi: 10.1056/NEJMoa070596. - DOI - PubMed
    1. Dimopoulos M, Spencer A, Attal M, et al. on behalf of the Multiple Myeloma (010) Study Investigators Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123–32. doi: 10.1056/NEJMoa070594. - DOI - PubMed
    1. Browman GP, Levine MN, Mohide EA, et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol. 1995;13:502–12. - PubMed
    1. Lyman GH, Khorana AA, Falanga A, et al. on behalf of the American Society of Clinical Oncology American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25:5490–505. doi: 10.1200/JCO.2007.14.1283. - DOI - PubMed
    1. National Institute for Health and Clinical Excellence (nice) Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy. London, UK: NICE; 2009. [Available online at: http://www.nice.org.uk/nicemedia/pdf/TA171Guidance.pdf; cited December 15, 2011]